Skip to content

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arena Pharmaceuticals Presented Phase 2 Clinical Data for Etrasimod in Ulcerative Colitis at the American College of Gastroenterology Annual Meeting
SAN DIEGO , Oct. 8, 2018 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that data from its OASIS Phase 2 clinical study for its investigational drug candidate etrasimod, a next-generation, oral, S1P receptor modulator with optimized activity being evaluated in
View HTML
Toggle Summary Arena Pharmaceuticals Reports Positive Long-Term Data from the Ongoing Open-Label Extension of the Phase 2 Trial Evaluating Ralinepag for Treatment of Pulmonary Arterial Hypertension
- Ralinepag demonstrated durable, long-term improvements in both PVR and 6MWD - Favorable long-term tolerability profile demonstrated SAN DIEGO , Oct. 2, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced positive data from a planned interim analysis of the ongoing
View HTML
Toggle Summary Arena Pharmaceuticals Reports Positive Phase 2a Results for Olorinab in Patients with Abdominal Pain Associated with Crohn's Disease
- Olorinab demonstrated a statistically significant improvement in abdominal pain over 8 weeks of treatment - All patients with evaluable data at week 8 exhibited a pre-defined clinical response of ≥30% change from baseline in AAPS - Treatment effects were demonstrated early and were consistent
View HTML
Toggle Summary Arena Pharmaceuticals to Host R&D Day on October 4 in New York City
SAN DIEGO , Sept. 21, 2018 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Company will host an R&D Day to outline key catalysts and new information on the clinical programs for its potentially first- or best-in-class late-stage investigational compounds:
View HTML
Toggle Summary Arena Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO , Sept. 20, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that members of its senior management team will participate in the upcoming investor conferences: Cantor Global Healthcare Conference – Presenting on Tuesday, October 2 , at 1:40 p.m.
View HTML
Toggle Summary Arena Pharmaceuticals Presents Preclinical Data for Olorinab at International Association for the Study of Pain World Congress
SAN DIEGO , Sept. 17, 2018 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that results from preclinical studies of its investigative drug candidate olorinab, a peripherally restricted, highly selective, full agonist of the cannabinoid receptor 2 (CB 2 ) in development
View HTML
Toggle Summary Arena Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO , Aug. 29, 2018 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that members of its senior management team will participate in the upcoming investor conferences: Wells Fargo Securities Global Healthcare Conference – Presenting on Wednesday, September 5 at 2:25
View HTML
Toggle Summary Arena Pharmaceuticals Presented Phase 1 Clinical Data for Ralinepag in Pulmonary Arterial Hypertension at the European Society of Cardiology
SAN DIEGO , Aug. 28, 2018 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that data from two Phase 1 clinical studies evaluating an extended-release (XR) formulation of its investigative drug candidate ralinepag, a next-generation, oral, selective and potent prostacyclin
View HTML
Toggle Summary Eisai Inc. Announces Positive Topline Results from CAMELLIA-TIMI61, a Large-Scale Cardiovascular Outcome Trial for the Anti-Obesity Agent BELVIQ
<p><strong>WOODCLIFF LAKE, N.J., JULY 17, 2018 – </strong>Eisai Inc. announced positive topline results from the <a href="https://clinicaltrials.gov/ct2/show/NCT02019264">CAMELLIA-TIMI 61</a> cardiovascular outcome trial. This 12,000 patient study of BELVIQ<strong><sup>®</sup></strong> (lorcaserin HCl) CIV 10 mg twice-daily was conducted at over 400 sites in eight countries including the United States in collaboration with the Thrombolysis in Myocardial Infarction (TIMI) Study Group and is the largest cardiovascular (CV) outcome trial to date for a weight loss medication.</p>
View HTML
Toggle Summary Arena Pharmaceuticals Appoints Life Sciences Industry Veteran Kieran T. Gallahue to Board of Directors
SAN DIEGO , July 10, 2018 /PRNewswire/ --&nbsp; Arena Pharmaceuticals, Inc. (Nasdaq: ARNA), a biopharmaceutical company focused on delivering novel, transformational medicines across multiple therapeutic areas, today announced the appointment of Kieran T. Gallahue as a non-executive director. Mr.
View HTML